Bone metastases represent the most common etiology of pain for patients with advanced cancer. In the United States, the most common treatment for pain caused by bone metastases in late-stage cancer cases is external beam radiotherapy in conjunction with opioids. An alternative or adjuvant to external radiotherapy is intravenous radiopharmaceutical treatment. This review explores the pros and cons of different radiopharmaceutical options, their advantages over traditional external beam radiotherapy, and the conditions for optimal efficacy.
Farhanghi M, Holmes RA, Volkert WA, et al.: Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992; 33(8): 1451-1458.
2.
Foley KM:Pain syndromes in patients with cancer. In Portenoy RK, Kanner RM (eds.): Pain Management: Theory and Practice. Philadelphia: F.A. Davis, 1996, 191-216.
3.
Coleman RE, Rubens RD:The clinical course of bone metastases from breast cancer. Br J Cancer. 1987; 55(1): 61-66.
4.
Jacox A, Carr DB, Payne R:Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
5.
Tong D, Gillick, Hendrickson FR: Palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982; 50(5): 893-899.
6.
Poulsen HS, Nielsen OS, Klee M, et al.: Palliative irradiation of bone metastases. Cancer Treat Rev. 1989; 16(1): 41-48.
7.
Payne R, Janjan N: Management of metastatic bone pain. Assessment and treatment of cancer pain. In Payne R, Patt RB, Hill CS (eds.): Progress in Pain Research and Management. Vol 12. Seattle: IASP Press, 1998.
8.
Janjan NA, Payne R, Podoloff D, et al.: Outcomes in a multidisciplinary clinic for bone metastasis. Proceedings of the 77th Annual Meeting of the American Radium Society, April 29-May 3, 1995, Paris, France.
9.
Fulfaro F, Casuccio A, Ticozzi C, et al.: The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain. 1998; 78(3): 157-169.
10.
Tannock IF, Osoba D, Stockler MR, et al.: Chemotherapy with mitoxantrone, plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end point. J Clin Oncol. 1996; 14(6): 1753-1755.
11.
Bennett A:The role of biochemical mediators in peripheral nociception and bone pain. Cancer. 1988; 7(1): 55-68. Review.
12.
Hungerford DS:Bone marrow pressure and intramedullary renography. In Owen R, Goodfellow J, Bullough P (eds.): Scientific Foundations of Orthopedics and Traumatology. London, England: Heineman, 1980, 357-361.
13.
Rosier RN, Hicks DG, Teot La, et al.: Mechanisms of bone metastasis. Assessment and treatment of cancer pain. In Payne R, Patt RB, Hill CS (eds.): Progress in Pain Research and Management Vol 12. Seattle: IASP Press, 1998.
Ishibe M, Rosier RN, Puzas JE:Activation of osteoblast insulin-like growth factor-II/cation-independent mannose-6-phosphate receptors by specific phosphorylated sugars and antibodies induce insulin-like growth factor-II effects. Endocr Res. 1991; 17(3-4): 357-366.
16.
Statkiewicz-Sherer MA, Visconti PJ, Ritenour ER:Radiation Protection in Medical Radiography. 3rd Edition. St. Louis, MO: Mosby, Inc., 1998.
17.
Atkins HL, Srivastava SC:Radiopharmaceuticals for bone malignancy therapy. J Nucl Med Technol. 1998; 26(2): 80-83.
18.
Robinson RG, Preston DF, Baxter KG, et al.: Clinical experience with Strontium-89 in prostatic and breast cancer. Semin Oncol. 1993; 20(3 suppl 2): 44-48. Review.
19.
Silberstein EB:The treatment of painful osteoblastic metastases: What can we expect from nuclear oncology? J Nucl Med. 1994; 35(12): 1994-1995.
20.
Edwards GK, Santoro J, Taylor A:Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89. J Nucl Med. 1994; 35(12): 1992-1993.
21.
Robinson RG, Preston DF, Spicer JA:Radionuclide therapy of intractable bone pain: Emphasis on strontium-89. Semin Nucl Med. 1992; 22(1): 28-32. Review.
22.
Schmeler K, Bastin K:Strontium-89 for symptomatic metastatic prostate cancer to bone: Recommendations for hospital patients. Hosp J. 1996; 11(2): 1-10.
23.
Elgazzar AH, Maxon HR:Radioisotope therapy for cancer related bone pain. Imag Ins. 1993; 2: 1-6.
24.
Porter AT, Benda R, Ben-Josef E: Palliation of metastases: Bone and spinal cord. In Gundersson, Tepper (eds.): Clinical Radiation Oncology. Churchill Livingstone, 2000.
25.
Blake GM, Zivanovic MA, McEwan AJB, et al.: Sr-89 therapy: Strontium kinetics in disseminated cancer of the prostate. Eur J Nucl Med. 1986; 12(9): 447-454.
26.
Breen SL, Powe JE, Porter AT:Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992; 33(7): 1316-1323.
27.
Ben-Josef E, Lucas DR, Vasan S, et al.: Selective accumulation of strontium-89 in metastatic deposits in bone: Radio histological correlation. Nucl Med Commun. 1995; 16(6): 457-463.
28.
Silberstein EB, Williams C:Strontium-89 therapy for the pain of osseous metastases. J Nucl Med. 1985; 26(4): 345-348.
29.
Robinson RG, Blake GM, Preston DF, et al.: Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989; 9(2): 271-281.
30.
Mertens WC, Porter AT, Reid RH, et al.: Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report. J Nucl Med. 1992; 33(8): 1437-1433.
31.
Tennvall J, Darte L, Lundgren R, et al.: Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Oncol. 1988; 27(4): 365-369.
32.
Laing AH, Ackery DM, Bayly RJ, et al.: Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991; 64(765): 816-822.
33.
McEwan AJB, Porter AT, Venner PM, et al.: An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunoconjugates Radiopharm. 1990; 3: 91-98.
34.
Lewington VJ, McEwan AJ, Ackery DM, et al.: A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991; 27(8): 954-958.
35.
Molina IL, Caceres W, Baez L, et al.: The effects of strontium-89 treatment on fibrinolysis and coagulation in prostate cancer patients. J Nucl Med. 2000; 41(Suppl): 265P-266P.
36.
Bolger JJ, Dearnaley DP, Kirk D, et al.: Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: Preliminary report of a multicenter trial. Semin Oncol. 1993; 20(3 Suppl 2): 32-33.
37.
Porter AT, McEwan AJ, Powe JE, et al.: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993; 25(5): 805-813.
38.
Porter AT, McEwan AJ:Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial. Semin Oncol. 1993; 20(3 Suppl 2): 38-43.
39.
Friedell HL, Storaasli JP:The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther Nucl Med. 1950; 64(4): 559-575.
40.
Silberstein EB:The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol. 1993; 20 (3 Suppl 2): 10-21.
41.
Mertens WC, Reid RH, Porter AT, et al.: Recent advances in radionuclide therapy of bone metastases. In Freeman L (ed.): Nuclear Medicine Annual. New York: Raven, 1992, 68-89.
42.
Samarium-153-lexidronam. Clinical Pharmacology Web site. Available at www.cponline.gsm.com. Accessed 1997.
43.
Samarium-153-lexidronam for painful bone metastases. Med Lett Drugs Ther. 1997; 39(1008): 83-84.
44.
Holmes RA:[153Sm] EDTMP: A potential therapy for bone cancer pain. Semin Nucl Med. 1992; 22(1): 41-45.
45.
Bayouth JE, Macey DJ, Kau LP, et al.: Dosimetry and toxicity of samarium-153EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994; 35(1): 63-69.
46.
Collins C, Eary JF, Donaldson G, et al.: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med. 1993; 34(11): 1839-1844.
47.
Alberts AS, Smit BJ, Louw WK, et al.: Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radioth Oncol. 1997; 43(2): 175-179.
48.
Holmes RA:153Sm JEDTMP: A potential therapy for bone cancer pain. Sem Nucl Med. 1992; 22(1): 41-45.
49.
Eary JF, Collins C, Stabin M, et al.: Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993; 34(7): 1031-1036.
50.
Li L, Laing ZL, Deng FH, et al.: 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. J Nucl Med. 2000; 41(Suppl): 265P.
51.
Maxon HR, Schroder LE, Hertzberg VS, et al.: Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Result of a double-blind crossover comparison with placebo. J Nucl Med. 1991; 32(10): 1877-1881.
52.
Englaro EE, Schroder LE, Thomas SR, et al.: Safety and efficacy of repeated sequential administrations of RE-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clin Nucl Med. 1992; 17(1): 41-44.
53.
Maxon HR, Thomas SR, Hertzberg VS, et al.: Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med. 1992; 22(1): 33-40.
54.
Brenner W, Kampen WU, Kampen AM, et al.: Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med. 2001; 42(2): 230-236.
55.
Han SH, Zonnenberg BA, deKlerk JMH, et al.: 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med. 1999; 40(4): 639-642.
56.
Kolesnikov-Gauthier H, Carpentier P, Depreux P, et al.: Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med. 2000; 41(10): 1689-1694.
57.
Maxon HR, Schroder LE, Washburn LC, et al.: Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med. 1998; 39(4): 659-663.
58.
Liepe K, Kropp J, Knapp F, et al.: Kinetics and therapeutic effect of rhenium-188 in palliative treatment of metastatic bone pain. Br J Cancer. 2003; 89(4): 625-629.
59.
Schmaljohann J, Guhlke S, Dudczak R, et al.: Kit-preparation of 188Re-HEDP: Comparison of three different formulations. J Nucl Med. 2000; 41(Suppl): 255P.
60.
Liepe K, Kropp J, Hliscs R, et al.: Radiation dose of 188Re-HEDP in bone metastases. J Nucl Med. 2000; 41(Suppl): 266P.
61.
Chen SL:Treatment of metastatic bone pain with 188Re-HEDP. J Nucl Med. 2000; 41(Suppl): 265P.
62.
Atkins HL:Overview of nuclides for bone pain palliation. Appl Radiat Isot. 1998; 49(4): 277-283.
63.
Srivastava SC, Atkins HL, Krishnamurthy GT, et al.: Treatment of metastatic bone pain with tin-117m stannic diethylenetriamine penta acetic acid: A phase I/II clinical study. Clin Cancer Res. 1998; 4(1): 61-68.
64.
Srivastava SC, Atkins HL, Krishnamurthy GT, et al.: Long-term analysis of clinical data from patients treated with Sn-117m DTPA for metastatic bone pain [abstract]. J Nucl Med. 1999; 40(Suppl): 65P.
65.
Srivastava SC, Meinken GE, Atkins HL, et al.: New tin-117m formulations for therapy of cancer in bone [abstract]. J Nucl Med. 1999; 40(Suppl); 121P.
66.
Bishayee A, Rao DV, Srivastava SC, et al.: Marrow-sparing effects of 117mSn (4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med. 2000; 41(12): 2043-2050.
67.
Giammarile F, Mognetti T, Blondet C, et al.: Bone pain palliation with 85Sr therapy. J Nucl Med. 1999; 40(4): 585-590.
68.
Kothari K, Samuel G, Banerjee S, et al.: Preparation and pharmacological evaluation of the 186 Re complex of a novel tetraphosphonate as a potential bone pain palliation agent. J Nucl Med. 2000; 41(Suppl): 247P.
69.
Macklis R, Lasher J:Palliative radiotherapy for skeletal metastases: Cost-substitution analyses and economic impact. J Oncol Manag. 1999; 8(2): 17-22.
70.
Skolnick AA:New study suggests radiation often underused for palliation. JAMA. 1998; 279(5): 343-344.
71.
Swedish Council on Technology Assessment in Health Care: The cost of radiotherapy in Sweden. Acta Oncol. 1996; 35(Suppl 6): 57-71.
72.
McEwan A, Amyotte G, McGowan D, et al.: A retrospective analysis of the cost effectiveness of treatment with Metastron (89Srchloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun. 1994; 15(7): 499-504.
73.
Wyndaele D, Adriaenssen I, Krug B, et al: Comparison of external radiation therapy and radionuclide therapy with 186 Re-HEDP in the treatment of painful bone metastases of breast cancer. J Nucl Med. 2000; 41(Suppl): 266P.
74.
Papatheofanis FJ:Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med. 1999; 40(9): 1420-1423.
75.
Brenner W, von Forstner C, Bruemmer C, et al.Myeloprotective effects of amifostine after treatment with high-dose 153Sm-EDTMP or 186Re-HEDP. J Nucl Med. 2000; 41(Suppl): 271P.
76.
Saga T, Sakahara H, Nakamoto Y, et al.: Enhanced therapeutic effect of radioimmunotherapy by the combination of whole-body mild hyperthermia. J Nucl Med. 2000; 41(Suppl): 271P.
77.
Mertens WC:Radionuclide therapy of bone metastases: Prospects for enhancement of therapeutic efficacy. Semin Oncol. 1993; 20(3 Suppl 2): 49-55. Review.
78.
Sciuto R, Maini CL, Tofani A, et al.: Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996; 17(9): 799-804.
79.
Geldof AA, de Rooij L, Versteegh RT, et al.: Combination 186Re-HEDP and Cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med. 1999; 40(4): 667-671.
80.
Lenarczyk M, Goddu SM, Rao DV, et al.: Biologic dosimetry of bone marrow: Induction of micronuclei in reticulocytes after exposure to 32P and 90Y. J Nucl Med. 2001; 42(1): 162-169.
81.
Silberstein EB:Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med. 1996; 37(2): 249-252.
